Can­cer biotech In­ten­si­ty Ther­a­peu­tics looks to pull in $16M+ IPO

Can­cer biotech In­ten­si­ty Ther­a­peu­tics launched an IPO as it aims to ad­vance a ther­a­py be­ing test­ed in sar­co­ma and breast can­cer.

The Con­necti­cut biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER